Inspire’s Ophthalmic Antibiotic AzaSite Gets FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm highlights more convenient dosing of conjunctivitis treatment over currently available therapies.
You may also be interested in...
Inspire Terminates Deal With FAES Farma For Oral Bilastine
Company ends collaboration following a meeting with FDA last year in which the agency recommended additional clinical trial work.
Inspire Terminates Deal With FAES Farma For Oral Bilastine
Company ends collaboration following a meeting with FDA last year in which the agency recommended additional clinical trial work.
Inspire Reports Positive Phase II Results For Allergic Rhinitis Spray
Firm tells “The Pink Sheet” DAILY it hopes to differentiate epinastine by focusing on its non-steroidal characteristic and less bitter taste.